Kenneth Krisko


I work closely with my clients to understand their business and strategic objectives and to structure and negotiate transactions to meet those objectives.

Kenneth Krisko's practice focuses on the representation of public and private life sciences companies in a broad range of commercial and corporate finance matters. He advises clients regularly with respect to complex commercial transactions designed to maximize the value of pharmaceutical products and technology assets, including technology licenses and acquisitions, research and development collaborations, distribution and manufacturing agreements, and profit-sharing and co-promotion arrangements.

Download full bio 


  • Merus Enters Collaboration With Eli Lilly to Develop New Generation of Cancer Treatments 

  • Hansa Biopharma Announces Collaboration with Sarepta 

  • Poseida Therapeutics – $224 Million IPO 

  • Therachon Sells to Pfizer for up to $810 Million 

  • Lodo Therapeutics Enters $970 Million Multi-Target Collaboration With Genentech 

  • View all


  • University of Virginia School of Law
    JD, 1995

  • Virginia Tech
    BS, Aerospace and Ocean Engineering

Admissions & Credentials

District of Columbia



  • American Bar Association

Rankings & Accolades

    Legal 500: Key Lawyer – Healthcare: Life Sciences (2021)